Business
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results
New Drug Application for VP-102 assigned PDUFA goal date of July 23, 2023 VP-102 has potential to address the approximately six million patients in the U.S.
About this update from Verrica Pharmaceuticals Inc.
[{"type":"text","content":"New Drug Application for VP-102 assigned PDUFA goal date of July 23, 2023 VP-102 has potential to address the approximately six million patients in the U.S. with molluscum contagiosum Dosing of first patient in Part 2 of Phase 2 study of VP-315 for treatment of basal cell carcinoma expected in 2Q 2023 Raised gross proceeds of $32.5 million in secondary offering; pro forma cash and cash equivalents to fund planned operations into 1Q 2024 WEST CHESTER, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the fourth quarter and year ended December 31, 2022. “We continue to execute across all aspects of our business, highlighted by the FDA’s recent acceptance of the filing of the resubmission of our NDA for VP-102, which is being developed for the treatment of molluscum contagiosum,” said Ted White, Verrica’s President and Chief Executive Officer. “Our potentially first-in-class oncolytic peptide immunotherapy, VP-315, for the treatment of basal cell carcinoma also continues to advance, and we remain on track to dose patients in Part 2 of our ongoing Phase 2 trial in the second quarter. “In parallel with our regulatory and clinical accomplishments, we continue to make progress in our pre-commercial activities as we prepare for a potential U.S. launch of what could potentially be the first FDA-approved therapy for molluscum – a condition afflicting millions of children each year in the U.S. Utilizing our innovative “Buy-and-Bill” commercial model, we believe shelf-stable products for in-office administration such as VP-102 can be efficiently distributed to reach this large and underserved patient population with minimal capital outlay for dermatology practices.” Business Highlights and Recent Developments VP-102 On February 27, 2023, the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) of July 23, 2023 for Verrica’s New Drug Application (NDA) for VP-102, which is being developed for the treatment of molluscum contagiosum (molluscum). In January, the Company announced that it resubmitted the NDA for VP-102 for the treatment of molluscum to the FDA.Verrica is seeking conditional approval to ...